Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and efficacy of TTI-101 given in combination with
Stereotactic Body Radiation Therapy (SBRT) in borderline resectable pancreatic ductal
adenocarcinoma.